IBPS provided cost efficient integrated end to end Product Development approach for one of their biologic assets. Together, we made remarkable progress on the project by having constructive collaboration with all stakeholders and received favorable overall FDA feedback for IND. We were also able to successfully negotiate a leaner BLA submission data package with FDA along with zero comments on CTA from local regulatory. We continue to drive the program to achieve timely milestones despite pandemic and travel restrictions